SPARC Share Price: FDA ka Rare Voucher mila, Share **8.7%** bhaga!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
SPARC Share Price: FDA ka Rare Voucher mila, Share **8.7%** bhaga!
Overview

Sun Pharma Advanced Research Company (SPARC) ke liye badi khabar! Unko USFDA se ek Rare Pediatric Disease Priority Review Voucher (PRV) mila hai. Yeh voucher Sezaby drug ke approval se juda hai aur company ke liye ek solid strategic asset ban gaya hai, jisse future mein paisa bhi bana sakte hain.

Socho, SPARC ko USFDA se ek super important 'Rare Pediatric Disease Priority Review Voucher' (PRV) mil gaya hai! Yeh voucher unki neonatal seizure therapy, Sezaby, ke approval ke baad mila hai. Sirf approval nahi, yeh voucher future mein kisi bhi dusre drug application ko jaldi review karwane mein help karta hai, matlab R&D speed boost!

Is zabardast khabar ke baad SPARC ka share price lagbhag 8.70% upar bhaga. Feb 3, 2026 ko, stock ₹145.11 ke aas paas trade ho raha tha. Pichle saal ki mandi se compare karein toh yeh ek badi baat hai, aur investors ko lagta hai is voucher ki asli value hai.

Historical data dekhein toh aise vouchers $200 million se $350 million tak mein bikte hain. Aur, yeh PRV program September 30, 2026 ke baad khatam ho sakta hai, toh SPARC ke paas ab time kam hai iska poora fayda uthane ka. Company ke CEO Anil Raghavan ne bhi kaha hai ki yeh voucher unhe "additional strategic flexibility" dega aur "pipeline development" ko accelerate karega.

Ab SPARC ki current financial halat thodi patli hai. Unka P/E ratio negative hai (around -12.0x to -16.2x), book value bhi negative (₹-10.8), aur ROCE toh -298% hai! Sales bhi last 5 saal mein 1.35% kam hui hai. Stock bhi saal tak 15.54% gira hai jabki Sensex badha hai, aur technicals bhi "mildly bearish" dikha rahe hain.

Lekin yeh PRV SPARC ke liye ek lifeline jaisa hai. Yeh turant ek catalyst hai aur agar company isse monetize karti hai, toh kaafi capital aa sakta hai jo R&D ya operational losses cover karne mein kaam aaega. Unki market cap ₹4,332 crore hai, jo badi pharma companies se kam hai, par voucher ki potential value isse kaafi zyada ho sakti hai.

Halanki company ki past performance aur technicals thode weak hain, 9 analysts ne is par 'Buy' rating di hui hai aur target ₹2,091 diya hai. Shayad woh is voucher ki power ko samajh rahe hain. Pharma sector mein, hamesha innovation aur accelerated regulatory pathways ko value diya jata hai, isliye SPARC ka yeh strategic asset bahut important ho sakta hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.